The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Newly-listed NGM Biopharmaceuticals needs its Nash project to impress in phase II, while Enanta must show that it also has a foot in the door in the liver disease.
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?